BA
The Boeing Company
BA has a slight edge over CYRX overall, supported by stronger fundamentals and lower modeled downside.
CYRX
Cryoport, Inc.
CYRX offers stronger modeled upside, but that advantage does not outweigh its weaker overall profile.
BA Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Stable | |
| Under pressure |
BA's profitability is currently healthy, and its revenue and cash flow are stable, but its balance sheet is under pressure.
CYRX Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Under pressure | |
| Weak |
CYRX's revenue is currently healthy, but its profitability, cash flow and balance sheet are under pressure.
BA PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 18x | $172 | — |
| Cheap | 51x | $496 | +189% |
| Fair | 82x | $790 | +360% |
| Expensive | 91x | $876 | +411% |
Historical ranges are pointers, not guarantees.
BA's PE is 18x, but its earnings don't support one, so it isn't a reliable read right now.
CYRX PE Valuation
CYRX has no meaningful PE right now: it lost money over the past year.
BA Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Returning to profit | |
| Growth | |
| Improving | |
| Limited | |
| Low |
Analysts expect BA to return to profit, with revenue growing. However, they disagree widely on these estimates.
CYRX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect CYRX's losses to shrink, with revenue growing.
BA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $9.66 | +$23.38 |
| Q2 2026 | $2.78 | +$19.33 |
| Q1 2026 | $2.53 | +$20.49 |
| Q4 2025 | $2.48 | +$20.84 |
| Q3 2025 | -$13.72 | -$0.83 |
| Q2 2025 | -$16.55 | -$10.93 |
| Q1 2025 | -$17.96 | -$14.42 |
| Q4 2024 | -$18.36 | -$14.69 |
BA has the edge over CYRX on earnings quality, reporting a profit while its opponent remains loss making.
CYRX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.89 | -176% |
| Q2 2026 | -$0.82 | -162% |
| Q1 2026 | $1.43 | +$3.77 |
| Q4 2025 | $1.40 | +$3.89 |
| Q3 2025 | $1.17 | +$4.56 |
| Q2 2025 | $1.33 | +$5.01 |
| Q1 2025 | -$2.34 | +$0.14 |
| Q4 2024 | -$2.49 | -$0.28 |
CYRX has swung to a loss: it lost $0.89 per share over the past year, after a profit the year before.
BA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.2B | +3.9% |
| Q2 2026 | $24.6B | +8% |
| Q1 2026 | $22.2B | +14% |
| Q4 2025 | $23.9B | +57% |
| Q3 2025 | $23.3B | +30% |
| Q2 2025 | $22.7B | +35% |
| Q1 2025 | $19.5B | +18% |
| Q4 2024 | $15.2B | -31% |
BA has the edge over CYRX on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 1.5% | +22 points |
| Q2 2026 | 0.6% | +1.4 points |
| Q1 2026 | 2% | -0.3 points |
| Q4 2025 | 37% | +61 points |
| Q3 2025 | -21% | +12 points |
| Q2 2025 | -0.8% | +5.7 points |
| Q1 2025 | 2.4% | +2.9 points |
| Q4 2024 | -25% | -26 points |
BA has the edge over CYRX on profitability, with a higher operating margin.
CYRX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $50.2M | +14% |
| Q2 2026 | $49M | +7.7% |
| Q1 2026 | $47.8M | +16% |
| Q4 2025 | $45.5M | -24% |
| Q3 2025 | $44.2M | -22% |
| Q2 2025 | $45.5M | -21% |
| Q1 2025 | $41M | -25% |
| Q4 2024 | $59.5M | +4% |
CYRX's revenue is recovering but still below its 2022 peak: $50M last quarter, up 14% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -18% | +4.9 points |
| Q2 2026 | -21% | +0.7 points |
| Q1 2026 | -20% | +3 points |
| Q4 2025 | -22% | +1.3 points |
| Q3 2025 | -22% | +6.5 points |
| Q2 2025 | -21% | +116 points |
| Q1 2025 | -23% | +16 points |
| Q4 2024 | -23% | +99 points |
CYRX's operating margin was −18% last quarter, up 4.9 points from the same quarter a year ago.
BA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $464M | +95% |
| Q2 2026 | $631M | +$831M |
| Q1 2026 | -$1.5B | +$836M |
| Q4 2025 | $375M | +$4.5B |
| Q3 2025 | $238M | +$2.2B |
| Q2 2025 | -$200M | +$4.1B |
| Q1 2025 | -$2.3B | +$1.6B |
| Q4 2024 | -$4.1B | -239% |
BA has the edge over CYRX on cash generation, producing positive trailing cash flow while its opponent burns cash.
CYRX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$40K | +$1.2M |
| Q2 2026 | -$8M | +$3.7M |
| Q1 2026 | -$6.2M | +$1.3M |
| Q4 2025 | -$4.5M | +$6.2M |
| Q3 2025 | -$1.3M | +$2.5M |
| Q2 2025 | -$11.7M | +$119K |
| Q1 2025 | -$7.5M | -$239K |
| Q4 2024 | -$10.7M | -$1.6M |
CYRX has burned cash in almost every quarter: −$19M over the past year, against −$31M the year before.
BA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.3% | +2.1M shares |
| 1 year | +4.3% | +32.8M shares |
| 3 years | +31% | +186M shares |
| 5 years | +35% | +204M shares |
| Available history | +40% | +227M shares |
BA has 793M diluted shares, up 4.3% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2019 | — |
CYRX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.4% | +211K shares |
| 1 year | +1.1% | +529K shares |
| 3 years | +3.6% | +1.7M shares |
| 5 years | +9.8% | +4.5M shares |
| Available history | +52% | +17.3M shares |
CYRX has the edge over BA on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $2M |
| Q3 2025 | $3.7M |
| Q4 2022 | $4.6M |
| Q3 2022 | — |
| Q2 2022 | $25M |
| Q1 2022 | $8.3M |
BA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 3.0x | Elevated |
| Q2 2026 | 5.7x | High |
| Q1 2026 | 6.0x | High |
| Q4 2025 | 6.9x | High |
| Q2 2024 | 361.8x | High |
| Q1 2024 | 36.1x | High |
| Q4 2023 | 36.4x | High |
| Q3 2023 | 96.1x | High |
BA's net debt is about 3.0 years of its operating earnings (EBITDA), down from more than 20 years a year ago.
CYRX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2021 | 110.0x | High |
| Q3 2021 | 24.2x | High |
CYRX's net debt is more than 20 years of its operating earnings (EBITDA).
BA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 31.1 | Neutral |
| Stochastic | 9.6 | Oversold |
BA's weekly RSI is 31 (neutral) and its Stochastic is 10 (oversold).
CYRX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 71.7 | Overbought |
| Stochastic | 78.1 | Neutral |
CYRX's weekly RSI is 72 (overbought) and its Stochastic is 78 (neutral).
BA PE vs Industrials Sector
| Metric | BA | Sector median | Relative |
|---|---|---|---|
| PE | 18x | 24x | 26% below |
| PE % | 0 | 58 | 58 pts below |
BA is trading at 18x earnings, a 26% discount to the Industrials sector's median of 24x, though its earnings don't support one.
CYRX PE vs Industrials Sector
| Metric | CYRX | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 24x | — |
CYRX has no meaningful PE right now: it lost money over the past year.
BA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $184.6 | 7.1% below |
| 20 week MA | $203.8 | 16% below |
| 50 week MA | $215.5 | 20% below |
| 100 week MA | $205.9 | 17% below |
| 200 week MA | $200.6 | 14% below |
BA is in a downtrend: it's below all five of its weekly moving averages, and 14% below its 200-week average.
CYRX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $17.9 | 12% above |
| 20 week MA | $16.7 | 20% above |
| 50 week MA | $13.1 | 53% above |
| 100 week MA | $10.4 | 94% above |
| 200 week MA | $12.4 | 63% above |
CYRX has the edge over BA on trend strength, trading above more of its moving averages.
BA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $330.1 | $217.2 | -34% |
| 2021 | $217.2 | $204.2 | -6% |
| 2022 | $204.2 | $189.1 | -7.4% |
| 2023 | $189.1 | $260.7 | +38% |
| 2024 | $260.7 | $180.7 | -31% |
| 2025 | $180.7 | $216.4 | +20% |
| 2026 YTD | $216.4 | $171.6 | -21% |
BA has finished lower in four of the last six years. It's down 21% so far in 2026.
CYRX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $16.2 | $45.8 | +182% |
| 2021 | $45.8 | $59.5 | +30% |
| 2022 | $59.5 | $16.4 | -72% |
| 2023 | $16.4 | $15.5 | -5.5% |
| 2024 | $15.5 | $7.80 | -50% |
| 2025 | $7.80 | $9.66 | +24% |
| 2026 YTD | $9.66 | $20.1 | +108% |
CYRX has the edge over BA on returns for 2026, with the stronger performance.